Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
optINAVO: Inavolisib + Fulvestrant in PIK3CA-Mutated, HR+, HER2- Advanced Breast Cancer
NCT07368998Phase 2Recruiting
- Sponsor
- Roche
- Start
- Feb 2026
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of inavolisib in breast cancer, sponsored by Roche. Started Feb 2026; status: recruiting.
02
Drugs
inavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07368998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07368998.